{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"55.000","floor":"50.000"},"ipodate":{"start":"2020-09-25 00:00:00","end":"2020-09-30 00:00:00"},"minimumcapital":"27777.12","subscribed":"654.41","marketcap":"156.03億","H_marketcap":"--","pe":"--","codesrate":"2.00","link":"https://staticpdf.iqdii.com/stockdata/notice/01952/2020/2020092500048_c.pdf","ipopricing":"55.000","resultdate":"2020-10-08 00:00:00","enddate":"2020-09-30 00:00:00","listeddate":"2020-10-09 00:00:00","issuenumber":"6354.70萬","issuenumberhK":"3177.40萬","issuenumberother":"3177.30萬","grayprice":"72.05","sponsors":"高盛(亞洲)有限責任公司,美林遠東有限公司","raisemoney":"328410.00萬","use":"1、60%或約1,970.4百萬港元用于我們的四款支柱產品；\n2、15%或約492.6百萬港元用于為我們管線中其他候選藥物的進行中及計劃臨床試驗、登記備案準備及潛在商業化提供資金；\n3、15%或約492.6百萬港元用于為我們的業務發展活動及擴展藥品管線提供資金；\n4、10%或約328.4百萬港元用作營運資金以及一般及行政用途。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,美林亞太有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,野村國際(香港)有限公司,錦沄資產管理有限公司","bookrunners":"高盛(亞洲)有限責任公司,美林亞太有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司,野村國際(香港)有限公司,錦沄資產管理有限公司","coordinator":"高盛(亞洲)有限責任公司,美林亞太有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,瑞士信貸(香港)有限公司","firstDayOpen":"70.55","IsEiio":0,"Interestdays":8,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E01952","name":"云頂新耀－Ｂ","fullname":"云頂新耀有限公司"},"institutioninfo":{"principaloffice":"中國上海市南京西路1266號上海恒隆廣場辦公樓1號樓6601–6606室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"傅唯","secretary":"印茵,劉綺華","telephone":"","substantialshareholders":"CBC集團(48.42%)","principalactivities":"公司是一家生物制藥公司，業務包括潛在全球同類首創或同類最佳療法的許用、臨床開發及商業化，以解決大中華及亞太區其他新興市場尚未得到滿足的醫療需要。","website":"http://www.everestmedicines.com"},"managerinfo":[{"managername":"傅唯","post":"主席兼執行董事","rankno":1},{"managername":"薄科瑞","post":"首席執行官兼執行董事","rankno":2},{"managername":"何穎","post":"首席財務官、總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"RA Capital Healthcare Fund, L.P.","shareholding":"6,340,500.0","percentage":9.98,"ReleaseDate":"2021-04-09 00:00:00","relatedparty":"RA Capital Management, L.P.","subsidiary":["RA Capital Healthcare Fund, L.P."],"InverstorType":"基金"},{"institutionname":"C-Bridge IV Investment Sixteen Limited","shareholding":"4,227,000.0","percentage":6.65,"ReleaseDate":"2021-04-09 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Janchor Partners Pan-Asian Master Fund","shareholding":"4,227,000.0","percentage":6.65,"ReleaseDate":"2021-04-09 00:00:00","relatedparty":"Janchor Partners Limited","subsidiary":["Janchor Partners Pan-Asian Master Fund"],"InverstorType":"基金"},{"institutionname":"GIC Private Limited","shareholding":"2,818,000.0","percentage":4.43,"ReleaseDate":"2021-04-09 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":49.91},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}